Elesclomol
| File:Elesclomol.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
N′1,N′3-dimethyl-N′1,N′3- bis(phenylcarbonothioyl)propanedihydrazide | |
| Identifiers | |
| CAS Number | 488832-69-5 |
| ATC code | none |
| PubChem | CID 300471 |
| Chemical data | |
| Formula | C19H20N4O2S2 |
| Molar mass | 400.518 g/mol[[Script error: No such module "String".]] |
Elesclomol (INN, codenamed STA-4783) is a drug that triggers apoptosis (programmed cell death) in cancer cells. It is being developed by Synta Pharmaceuticals and GlaxoSmithKline as a chemotherapy adjuvant, and has received both fast track and orphan drug status from the U.S. Food and Drug Administration for the treatment of metastatic melanoma.[1] Synta Pharmaceuticals announced on February 26, 2009 the suspension of all clinical trials involving Elesclomol due to safety concerns.[2]. In March 2010, Synta announced that the FDA had approved resuming clinical development of elesclomol, and that they expected to initiate one or more clinical trials for elesclomol in the second half of the year[3].
In a small, randomized phase II study, elesclomol was shown to significantly increase progression-free survival in people with metastatic melanoma when given in addition to paclitaxel (Taxol).[4]
Mechanism of action
Elesclomol induces oxidative stress by provoking a buildup of reactive oxygen species within cancer cells.[5]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 40px | This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. |
- ↑ "Synta And GlaxoSmithKline Announce Elesclomol Granted Orphan Drug Designation By The FDA" (Press release). Medical News Today. January 30, 2008. http://www.medicalnewstoday.com/articles/95590.php. Retrieved November 30, 2008.
- ↑ "Synta Pharmaceuticals press release". February 26, 2009.
- ↑ "Synta Announces Elesclomol Clinical Development to Resume". March 2, 2010.
- ↑ "Prous Science Molecule of the Month: Elesclomol". Thomson Reuters. December 2007. Retrieved November 30, 2008.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Chemotherapeutic adjuvants
- Orphan drugs
- Hydrazides
- Antineoplastic and immunomodulating drug stubs
